TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05730777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Bifidum Oral Capsule
Description: Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in the control group will receive conventional antitumor treatment only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients in the control group will receive conventional antitumor treatment only.
Study: NCT05341661

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Butterfly Prostatic Retraction Device
Description: Implantation of the Butterfly device
Study: NCT05730777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients in the control group will receive conventional antitumor treatment only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients in the control group will receive conventional antitumor treatment only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients in the control group will receive conventional antitumor treatment only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients in the control group will receive conventional antitumor treatment only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atlizumab
Description: Patients in the control group will receive conventional antitumor treatment only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atlizumab
Description: Patients in the control group will receive conventional antitumor treatment only.
Study: NCT05827900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training
Description: Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
Study: NCT06331078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Square Stepping Exercise training
Description: The experimental group will have Square Stepping Exercise training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Individuals in the aerobic control cohort will partake in a treadmill walking session.
Study: NCT05898282

Intervention type: OTHER
Intervention: observation
Description: since this is a cross sectional observational study any form of intervention was not applicable
Study: NCT04890275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restricted resistance exercise (BFR)
Description: Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise without blood flow restricted (NON-BFR)
Description: Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
Study: NCT06091410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron-containing COVID-19 vaccine
Description: The COVID-19 vaccine approved for use in the 2023-2024 season

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Omicron-containing COVID-19 vaccine
Description: The COVID-19 vaccine approved for use in the 2023-2024 season

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: influenza vaccine
Description: inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
Study: NCT05804877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based cognitive therapy
Description: Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mental health education
Description: The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
Study: NCT04883671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
Study: NCT05254184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
Description: administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
Study: NCT05169346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Closed Loop Real Time fMRI Neurofeedback
Description: Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Closed Loop Real Time fMRI Neurofeedback
Description: Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
Study: NCT06233838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KHA80 hemoperfusion treatment
Description: On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
Study: NCT06441747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
Study: NCT05477745

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
Study: NCT06048523

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Patient cohort
Description: * For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control cohort
Description: * controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up
Study: NCT04829344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Ophthalmic Solution
Study: NCT06173219

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with immunotherapy
Description: (1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
Study: NCT05105139

Intervention type: OTHER
Intervention: Allantoin/ Coal Tar/ Clioquinol
Description: Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use

Intervention type: OTHER
Intervention: Allantoin/ Coal Tar/ Clioquinol/ Triclosan
Description: Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
Study: NCT06011473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM (FreeStyle Libre 3)
Description: FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3
Study: NCT05079893

Intervention type: OTHER
Intervention: Case control study
Description: Observational case control study

Intervention type: OTHER
Intervention: Case control study
Description: Observational case control study
Study: NCT04590469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID WHELD
Description: COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
Study: NCT04857385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial artery hemostasis
Description: Each of the devices will be assessed for radial artery hemostasis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial artery hemostasis
Description: Each of the devices will be assessed for radial artery hemostasis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery hemostasis
Description: Each of the devices will be assessed for radial artery hemostasis.
Study: NCT05760378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: TKI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: PD1 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: PD1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Description: TPC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Description: TPC
Study: NCT05330845

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IL6 assessment
Description: Blood IL6 will be assessed during trial

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CRP and PCT assessment
Description: Blood CRP and PCT will be assessed during trial
Study: NCT06077695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education
Description: The themes covered concern head trauma in the chronic phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education
Description: The themes covered concern head trauma in the chronic phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic education
Description: The themes covered concern head trauma in the chronic phase.
Study: NCT04665479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based legacy-making intervention through digital storytelling
Description: A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
Study: NCT04964622

Intervention type: DRUG
Group type: OTHER
Intervention: nurofen
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nurofen
Description: tablet
Study: NCT05644912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Description: Transanal irrigation (TAI) with new catheter on subjects experienced in using TAI with balloon catheter.
Study: NCT06282796

Intervention type: DEVICE
Intervention: Echocardiography
Description: Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software
Study: NCT01360957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black cumin water extract as a traditional medicine
Description: to be given orally in a dosage of 30 ml trice daily for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black cumin water extract as a traditional medicine
Description: to be given orally in a dosage of 30 ml trice daily for 60 days
Study: NCT06530914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003 combined with Pucotenlimab
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003 combined with Pucotenlimab+Cisplatin
Description: All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
Study: NCT06534476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients who agreed to participate in the study and met the inclusion criteria were interviewed face to face before the HD session and their verbal and written permissions were obtained by reading the voluntary consent form. The researcher interviewed the patients one-on-one and provided information about the purpose of the study and the training program. Then, scale forms were applied to the patients. In order not to interrupt the training and not to distract the patients in this group, a separate room in the Dialysis Unit was used during the training. The education booklet Living with Hemodialysis on hemodialysis management prepared in line with the literature was given to the patients by the researcher. The training of a patient lasted an average of 40-50 minutes. During and at the end of the training, the patients' questions were answered in the training room.
Study: NCT06270823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee-to-chest-flexion manoeuvre
Description: The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
Study: NCT04863066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: The presence of latent infected cells remains a key barrier to HIV-1 functional cure. Current approach to reducing the latent HIV reservoir is to reactivate virus-containing cells to make them be detected and eliminated by host defense. Endogenous cytotoxic T-lymphocytes (CTL) may not be adequate because of cellular exhaustion and immune escape of virus. We have designed a kind of CAR-T cell based on CTL engineered to express a scFv of a broadly neutralizing anti-HIV antibody. According to our preclinical studies, CAR-T cells strongly eradicated HIV-1-infected target cells making them a particularly suitable candidate to reach a functional HIV cure. In this clinical trial, we mainly intend to evaluate the safety of CAR-T-Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after antiviral therapy.
Study: NCT06507267

Intervention type: OTHER
Intervention: Pain and Clinical Reflections in Pelvic Congestion Syndrome
Description: Pain and Clinical Reflections in Pelvic Congestion Syndrome
Study: NCT05328531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection
Description: 150 mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection
Description: 150 mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection
Description: 150 mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection
Description: 150 mg/1ml/bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection
Description: 150 mg/1ml/bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Genakumab for Injection
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
Study: NCT04955639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of Care - Control Smoking Cessation Program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pivot
Description: Pivot Program Smoking Cessation Program
Study: NCT06215274

Intervention type: OTHER
Intervention: Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.
Description: The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).
Study: NCT06098443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety \& depression in patients with ESRD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
Study: NCT05160402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator
Study: NCT05020886

Intervention type: BEHAVIORAL
Intervention: turning task
Description: Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.

Intervention type: BEHAVIORAL
Intervention: turning task
Description: Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
Study: NCT04749420

Intervention type: OTHER
Intervention: Survey study
Description: Cervical Radiculopathy Impact Scale (CRIS) will be applied
Study: NCT04691765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: escalating doses of drug will be administered to 3 groups of 4 patients for 7 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: escalating doses of drug will be administered to 3 groups of 4 patients for 7 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
Study: NCT06059742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy with Rhythmic acoustic stimulation
Description: Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation Therapy without Rhythmic acoustic stimulation
Description: Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
Study: NCT05489679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC682
Description: Participants will receive AC682 by mouth daily in 28-day cycles.
Study: NCT05455749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: holoBLG
Description: holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)